Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bullseye On OTC Reproductive Drug Approvals In US After Federal Judge Questions FDA Expertise?

Apr 11 2023

• By Malcolm Spicer

• Source: Shutterstock

Related Content

What’s Next For FDA In Face Of Opposing Mifepristone Injunctions

Apr 09 2023

Court Ruling Compels Emergency Contraceptives Over The Counter

Apr 08 2013

Allowing States To Ban Abortion Services Increases Calls For Making Birth Control Available OTC

Jun 24 2022

Age-Restriction Labeling, Behind-The-Counter Sales Likely In HRA's US OTC Contraceptive NDA

Aug 25 2022

US FDA Requests More Information, Needs More Time To Review Birth Control OTC Switch Proposal

Oct 27 2022

For First US OTC Birth Control Application, FDA Extends Time For Advisory Panel Discussion

Mar 29 2023

Additional Topics

International United States US States Prescription To OTC Switch Legal Issues FDA Business Strategies Commercial Compliance Consumer Drug Safety Drug Approval Standards Ingredients Manufacturing OTC Drugs Policy Politics Regulation Safety Supply Chain

More from Rx-to-OTC Switch

More from Health

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window